These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 12399880)
1. [Sequelae of improved prognosis of SLE]. Manger K; Manger B Z Rheumatol; 2002 Oct; 61(5):532-3. PubMed ID: 12399880 [No Abstract] [Full Text] [Related]
2. [Special problems with long-term studies of SLE]. Becker A; Gromnica-Ihle E; Schneider M Z Rheumatol; 2002 Oct; 61(5):519-20. PubMed ID: 12399878 [No Abstract] [Full Text] [Related]
3. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965 [TBL] [Abstract][Full Text] [Related]
4. [Psoriasis and systemic lupus erythematosus: a rare association with specific therapeutic problems]. Astudillo L; Sailler L; Carreiro M; Dahan S; Ollier S; Arlet P Ann Med Interne (Paris); 2003 Feb; 154(1):3-6. PubMed ID: 12746653 [TBL] [Abstract][Full Text] [Related]
5. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ostendorf B; Iking-Konert C; Kurz K; Jung G; Sander O; Schneider M Ann Rheum Dis; 2005 Apr; 64(4):630-3. PubMed ID: 15345502 [TBL] [Abstract][Full Text] [Related]
7. Etanercept-associated SLE with lupus nephritis. Neradová A; Stam F; van den Berg JG; Bax WA Lupus; 2009 Jun; 18(7):667-8. PubMed ID: 19433471 [No Abstract] [Full Text] [Related]
8. [Lupus nephritis as a factor of atherosclerosis risk in patients with systemic lupus erythematosus]. Serikova SIu; Kozlovskaia NL; Shilov EM Ter Arkh; 2008; 80(6):52-8. PubMed ID: 18655477 [TBL] [Abstract][Full Text] [Related]
9. Pregnant adolescents and youth with systemic lupus erythematosus: can new data inform our approach to young women with SLE? Kaufman M J Rheumatol; 2008 Jul; 35(7):1240-1. PubMed ID: 18609731 [No Abstract] [Full Text] [Related]
10. Effects of rituximab on resistant SLE disease including lung involvement. Reynolds JA; Toescu V; Yee CS; Prabu A; Situnayake D; Gordon C Lupus; 2009 Jan; 18(1):67-73. PubMed ID: 19074171 [TBL] [Abstract][Full Text] [Related]
11. Treatment of SLE. Your CE topic (No. 38). The treatment of systemic lupus erythematosus. Bergman HD J Pract Nurs; 1989 Mar; 39(1):50-7. PubMed ID: 2926676 [No Abstract] [Full Text] [Related]
12. Hydroxychloroquine-induced pigmentation in two patients with systemic lupus erythematosus. Reynaert S; Setterfield J; Black MM J Eur Acad Dermatol Venereol; 2006 Apr; 20(4):487-8. PubMed ID: 16643169 [No Abstract] [Full Text] [Related]
13. Diplopia in a patient under hydroxychloroquine for systemic lupus erythematosus. Sabbagh M Rev Rhum Engl Ed; 1997 Jan; 64(1):65. PubMed ID: 9051865 [No Abstract] [Full Text] [Related]
14. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Jónsdóttir T; Gunnarsson I; Risselada A; Henriksson EW; Klareskog L; van Vollenhoven RF Ann Rheum Dis; 2008 Mar; 67(3):330-4. PubMed ID: 17827182 [TBL] [Abstract][Full Text] [Related]
15. TNF inhibition in SLE: where do we stand? Aringer M; Smolen JS Lupus; 2009 Jan; 18(1):5-8. PubMed ID: 19074162 [No Abstract] [Full Text] [Related]
16. Effect of severe neuropsychiatric manifestations on short-term damage in systemic lupus erythematosus. Fragoso-Loyo HE; Sánchez-Guerrero J J Rheumatol; 2007 Jan; 34(1):76-80. PubMed ID: 17143970 [TBL] [Abstract][Full Text] [Related]